8-K: Spero Therapeutics Reports Q4/FY25 Results, FDA Sets Tebipenem HBr PDUFA Date

Spero Therapeutics announced strong Q4 and full-year 2025 financial results, driven by collaboration revenue, and confirmed the FDA's PDUFA date for tebipenem HBr as June 18, 2026.

Summary

• Reported net income of $31.5 million for the fourth quarter of 2025, a significant improvement from a net loss of $(20.9) million in the fourth quarter of 2024.
• Full-year 2025 net income was $8.6 million, reversing a net loss of $(68.6) million in 2024.
• Total revenue for Q4 2025 increased to $41.3 million from $15.0 million in Q4 2024, primarily due to collaboration revenue from GSK and Pfizer.
• Full-year 2025 total revenue rose to $66.8 million from $48.0 million in 2024.
• Research and development expenses decreased significantly to $5.6 million in Q4 2025 and $38.5 million for the full year 2025, due to reduced clinical trial activity for the PIVOT-PO trial.
• General and administrative expenses also decreased in both Q4 and full year 2025.
• Resubmitted the tebipenem HBr New Drug Application (NDA) to the FDA in December 2025 for complicated urinary tract infections (cUTI).
• The FDA has set a Prescription Drug User Fee Act (PDUFA) date of June 18, 2026, for tebipenem HBr.
• Cash and cash equivalents stood at $40.3 million as of December 31, 2025, estimated to fund operations into 2028.
• Received a $25 million milestone payment from GSK in Q1 2026 following the NDA resubmission.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive update, driven by a significant financial turnaround, successful regulatory progress for a key drug candidate, and a strong cash runway, indicating robust operational execution and potential for future growth.

Positives

• Significant turnaround from net loss to net income in both Q4 and full year 2025, with Q4 2025 net income at $31.5 million and FY 2025 net income at $8.6 million.
• Substantial increase in total revenue, reaching $41.3 million in Q4 2025 and $66.8 million for FY 2025, driven by collaboration agreements with GSK and Pfizer.
• Successful resubmission of tebipenem HBr NDA to the FDA in December 2025.
• FDA has set a PDUFA date of June 18, 2026, for tebipenem HBr, providing a clear regulatory timeline.
• Positive Phase 3 PIVOT-PO trial results, demonstrating non-inferiority and a consistent safety profile for tebipenem HBr.
• Strong cash position of $40.3 million as of December 31, 2025, with an estimated runway into 2028.
• Receipt of a $25 million milestone payment from GSK in Q1 2026 following the NDA resubmission.
• Reduced R&D and G&A expenses, indicating improved cost management and efficiency.

Negatives

• Cash, cash equivalents and marketable securities decreased by $12.6 million from $52.9 million in December 2024 to $40.3 million in December 2025.
• Total assets decreased by $41.6 million from $110.5 million in December 2024 to $68.9 million in December 2025.

Risks

• Uncertainty regarding FDA approval of tebipenem HBr and the timing of any such approval, including potential regulatory delays.
• Possibility that the FDA may require additional clinical data or impose labeling restrictions that could delay approval or reduce commercial prospects.
• Challenges in achieving a successful commercial launch and establishing market acceptance for tebipenem HBr.
• Reliance on third parties (GSK and Meiji) to manufacture, develop, and commercialize product candidates, if approved.
• Reliance on GSK's sole discretion to further develop and commercialize tebipenem HBr under the exclusive license agreement.
• Need for additional funding beyond current cash resources.
• Ability to retain key personnel.
• Whether current cash resources will be sufficient to fund continuing operations for the anticipated periods.

Future Outlook

Spero Therapeutics anticipates the FDA's decision on tebipenem HBr by the PDUFA date of June 18, 2026. The company is exploring opportunities to expand its portfolio of clinical-stage product candidates and estimates its current cash and cash equivalents will fund operations into 2028. Tebipenem HBr, if approved, has the potential to be the first oral carbapenem antibiotic for US patients with cUTI and set a new standard of care.

Management Comments

• "2025 was marked by important progress across the tebipenem HBr program in cUTI, including completion of the global Phase 3 trial and resubmission of the NDA."
• "With our licensing partner GSKs global leadership in anti-infectives, tebipenem HBr, if approved, has the potential to address an important need and meaningfully improve treatment options for patients with cUTI."
• "We look forward to the FDAs decision in late June as we continue to execute our business strategy to deliver innovative therapies."

Industry Context

StockSavvy.ai notes that the successful resubmission of the tebipenem HBr NDA and the setting of a PDUFA date are critical milestones in the biopharmaceutical industry, particularly for companies developing novel antibiotics. The focus on cUTI addresses a significant unmet medical need, as antibiotic resistance continues to be a global health challenge. The partnership with GSK, a leader in anti-infectives, provides a strong commercialization pathway, potentially positioning tebipenem HBr as a key player in the oral carbapenem market, which could disrupt traditional IV treatment paradigms.

Comparison to Industry Standards

• The successful Phase 3 PIVOT-PO trial, demonstrating non-inferiority to intravenous imipenem-cilastatin, aligns with industry standards for efficacy in antibiotic development. Imipenem-cilastatin (e.g., Primaxin) is a well-established IV carbapenem, making the oral non-inferiority a strong comparative result.
• The safety and tolerability profile of tebipenem HBr, consistent with the carbapenem class, suggests it meets expected safety benchmarks for this type of antibiotic.
• The estimated cash runway into 2028, bolstered by collaboration revenue and milestone payments, positions Spero favorably compared to many clinical-stage biotechs that frequently face near-term funding challenges.

Related Party Transactions

• Collaboration revenue from GSK and Pfizer, which are licensing partners, contributed significantly to total revenue.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, clear regulatory pathway for tebipenem HBr, extended cash runway, and potential for future milestone payments and drug approval.
• Patients with cUTI: Potential for a new, effective oral treatment option (tebipenem HBr) if approved, offering an alternative to IV carbapenems.
• Employees: Continued focus on advancing therapies and exploring portfolio expansion suggests stability and potential growth opportunities.
• GSK (Licensing Partner): Progress towards FDA approval for tebipenem HBr aligns with their commercialization strategy and could lead to market entry.

Next Steps

• Anticipate FDA decision on tebipenem HBr by the PDUFA date of June 18, 2026.
• Continue to execute the business strategy to deliver innovative therapies.
• Complete obligations under the License Agreement with GSK.
• Advance other corporate activities, including exploring opportunities to expand the portfolio of clinical-stage product candidates.
• Refer to the Annual Report on Form 10-K for further financial details.

Key Dates

Recommendation

The filing presents a compelling case for a strong buy recommendation. Spero Therapeutics has achieved a significant financial turnaround, moving from substantial losses to profitability in both the fourth quarter and full year 2025, driven by increased collaboration revenue and disciplined cost management. The most critical development is the successful resubmission of the tebipenem HBr NDA and the FDA's setting of a PDUFA date for June 18, 2026. This provides a clear, near-term catalyst for potential market approval of a drug that demonstrated non-inferiority to an IV standard of care in Phase 3 trials, addressing a high unmet need in cUTI. The company's cash runway into 2028, bolstered by a recent $25 million milestone payment, provides financial stability, mitigating immediate funding concerns. While regulatory risks remain, the progress made, combined with a strong licensing partner in GSK, positions Spero for substantial upside if tebipenem HBr receives approval.

Keywords

Spero Therapeutics, SPRO, Tebipenem HBr, cUTI, Complicated Urinary Tract Infections, Pyelonephritis, FDA, NDA, PDUFA, GSK, Biopharmaceutical, Clinical-stage, Antibiotic, Phase 3 trial, Financial Results, Net Income, Revenue, Cash Runway, Drug Approval